25 To 99 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.3)
-
Publication number: 20110212886Abstract: The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare. The present invention further relates to pharmaceutical compositions comprising peptides derived from casein in the form of a sterile solution, which compositions are clear and substantially devoid of micelles.Type: ApplicationFiled: May 13, 2011Publication date: September 1, 2011Applicants: MILEUTIS LTD., State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research OrganizationInventors: Jose Mario Iscovich, Nissim Silanikove, Javier Iscovich
-
Publication number: 20110212108Abstract: The present invention resides in the discovery that the specific interaction between neuregulin 1 (NRG1) and integrin is important for ErbB signaling, which in turn plays an important role in cellular signaling in various physiological processes such as cell proliferation, especially in cancer cells overexpressing ErbB family members. Thus, this invention provides for a novel method for inhibiting ErbB signaling by using an inhibitor of NRG1-integrin binding. A method for identifying inhibitors of NRG1-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting ErbB signaling.Type: ApplicationFiled: May 11, 2009Publication date: September 1, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Yoshikazu Takada
-
Publication number: 20110212896Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.Type: ApplicationFiled: September 16, 2010Publication date: September 1, 2011Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
-
Patent number: 8007813Abstract: The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain.Type: GrantFiled: March 26, 2004Date of Patent: August 30, 2011Assignees: Apogenix GmbH, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen RechtsInventor: Henning Walczak
-
Publication number: 20110206752Abstract: Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2, its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.Type: ApplicationFiled: July 24, 2009Publication date: August 25, 2011Applicants: BCN PEPTIDES, S.A., DIVERDRUGS, S.L.Inventors: Cristina Carreno Serraima, Wim Van Den Nest, Antonio Ferrer Montiel, Maria Camprubi Robes, Jimena Fernandez Carneado, Berta Ponsati Obliols
-
Publication number: 20110207677Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc.Type: ApplicationFiled: June 2, 2009Publication date: August 25, 2011Inventor: Christophe Bonny
-
Publication number: 20110206723Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.Type: ApplicationFiled: February 24, 2011Publication date: August 25, 2011Inventors: Per-Åke Albertsson, Charlotte Albertsson-Erlanson
-
Publication number: 20110207678Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.Type: ApplicationFiled: February 7, 2011Publication date: August 25, 2011Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: David Naor, Shlomo Nedvetzki, Itshak Golan, Irina Kessel, Lora Melnik
-
Publication number: 20110206674Abstract: The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: ApplicationFiled: January 31, 2011Publication date: August 25, 2011Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
-
Publication number: 20110206760Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.Type: ApplicationFiled: July 20, 2009Publication date: August 25, 2011Applicant: COMPUGEN LTD.Inventors: Yossef Kliger, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
-
Patent number: 8003108Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 25, 2006Date of Patent: August 23, 2011Assignees: Amgen Inc., UCB SAInventors: Hsieng Sen Lu, Christpher Paszty, Martyn Kim Robinson, Alistair James Henry, Kelly Sue Warmington, John Latham, Alastair Lawson, David Winkler, Aaron George Winters
-
Publication number: 20110201542Abstract: Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with oxidative, psychological and/or physical stress, including but not limited to extreme exertion, ischemia, infarct, and damage associated with reperfusion of ischemic or transplanted tissues.Type: ApplicationFiled: April 27, 2011Publication date: August 18, 2011Applicant: The Board of Trustees of the University of IllinoisInventor: Herve Y. Sroussi
-
Publication number: 20110195911Abstract: A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits IFG-R1 activity, as well as a method of inhibiting a IGF1R in a cell, a method of treating or preventing IGF1R-mediated disease, and related compounds, compositions, and methods.Type: ApplicationFiled: March 27, 2009Publication date: August 11, 2011Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Nadya I. Tarasova, Sergey G. Tarasov
-
Publication number: 20110195128Abstract: Use of glycomacropeptide to treat or prevent gout, use of one or more phospholipids and one or more gangliosides to treat or prevent gout, or use of glycomacropeptide and one or more phospholipids and one or more gangliosides to treat or prevent gout.Type: ApplicationFiled: October 9, 2009Publication date: August 11, 2011Inventors: Kay Patricia Palmano, Alastair Kenneth Hugh MacGibbon, Nicole Jane Moore Dalbeth
-
Publication number: 20110195904Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: April 5, 2011Publication date: August 11, 2011Applicant: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. YOUNG, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
-
Publication number: 20110195900Abstract: Novel peptidic pth receptor agonists and methods of using the same are provided.Type: ApplicationFiled: August 19, 2009Publication date: August 11, 2011Applicant: FERRING B.V.Inventors: Claudio D. Schteingart, Javier Sueiras-Diaz
-
Patent number: 7994116Abstract: The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.Type: GrantFiled: August 14, 2008Date of Patent: August 9, 2011Assignee: Pharmasurgics In Sweden ABInventor: Kjell Olmarker
-
Patent number: 7994136Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.Type: GrantFiled: May 19, 1989Date of Patent: August 9, 2011Assignee: Amgen Inc.Inventors: Keith E. Langley, Yves A. DeClerck, Thomas C. Boone
-
Patent number: 7994121Abstract: The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.Type: GrantFiled: August 21, 2007Date of Patent: August 9, 2011Assignee: Trustees of Tufts CollegeInventors: William W. Bachovchin, Hung-Sen Lai, David George Sanford
-
Publication number: 20110190223Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: ApplicationFiled: February 14, 2011Publication date: August 4, 2011Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Steven M. Ruben, Craig A. Rosen, Gregory A. Endress
-
Publication number: 20110190210Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: ApplicationFiled: January 27, 2011Publication date: August 4, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Avner ADINI, Robert D'AMATO
-
Publication number: 20110190218Abstract: The present invention relates to a polypeptide having antitumor properties, to a vector encoding said polypeptide, to a host cell containing said vector, to uses of said polypeptide in the manufacture of a medicament for the treatment of cancer in patients, to a method comprising binding said polypeptide to molecular chaperones, and to a pharmaceutical composition containing said polypeptide.Type: ApplicationFiled: July 28, 2009Publication date: August 4, 2011Applicant: KARLSRUHE INSTITUTE OF TECHNOLOGYInventors: Andrew C. B. Cato, Liubov Shatkina, Katja Jehle, Danilo Maddalo
-
Publication number: 20110189188Abstract: Provided is a gp96-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.Type: ApplicationFiled: March 12, 2009Publication date: August 4, 2011Applicant: COMPUGEN LTD.Inventors: Yossef Kliger, Ofer Levy, Itamar Borukhov, Anat Amir, Anat Oren
-
Publication number: 20110190215Abstract: The amino acid sequences of peptides are disclosed.Type: ApplicationFiled: May 15, 2009Publication date: August 4, 2011Inventor: Marian L. Kruzel
-
Patent number: 7989585Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.Type: GrantFiled: August 10, 2007Date of Patent: August 2, 2011Assignee: Eli Lilly and CompanyInventors: Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann
-
Publication number: 20110183922Abstract: The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides.Type: ApplicationFiled: August 14, 2007Publication date: July 28, 2011Applicant: University of MiamiInventor: Richard L. Rotundo
-
Publication number: 20110183921Abstract: Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided.Type: ApplicationFiled: May 17, 2006Publication date: July 28, 2011Applicant: jojomed GmbHInventor: Nalân Utku
-
Publication number: 20110182921Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.Type: ApplicationFiled: December 29, 2010Publication date: July 28, 2011Inventors: Anne DE GROOT, William Martin, Daniel S. Rivera
-
Publication number: 20110183917Abstract: The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof.Type: ApplicationFiled: June 5, 2009Publication date: July 28, 2011Inventors: Wuyuan Lu, Davide Zella, Min Liu, Changqing Li
-
Publication number: 20110183889Abstract: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.Type: ApplicationFiled: August 28, 2008Publication date: July 28, 2011Applicant: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab
-
Patent number: 7985736Abstract: The present invention relates to compositions to treat CaV2 disorders. The invention also relates to methods treating CaV2 disorders. The invention further relates to kits for treating CaV2 disorders in a subject. The invention further relates to methods of identifying novel treatments for treating Cav2 disorders in a subject.Type: GrantFiled: December 14, 2005Date of Patent: July 26, 2011Assignee: The John Hopkins UniversityInventors: David T. Yue, Heather L. Agler
-
Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
Patent number: 7985729Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.Type: GrantFiled: April 21, 2010Date of Patent: July 26, 2011Assignee: House Research InstituteInventors: David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha -
Publication number: 20110178031Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.Type: ApplicationFiled: March 13, 2009Publication date: July 21, 2011Applicant: CTI BIOInventors: Jong-Ook Lee, Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim
-
Publication number: 20110178020Abstract: Isolated fusion polypeptides are provided that are comprised of a cell-penetrating polypeptide and a SNARE polypeptide aptamer. Further provided are methods for inhibiting neutrophil granule exocytosis that comprise contacting a neutrophil with a fusion polypeptide including a cell-penetrating polypeptide and a SNARE polypeptide aptamer such that the fusion polypeptide enters the neutrophil and inhibits neutrophil granule exocytosis. Also provided are methods for treating a neutrophil-mediated inflammatory disorder by inhibiting SNARE-associated exocytosis in neutrophils.Type: ApplicationFiled: July 28, 2009Publication date: July 21, 2011Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Kenneth R. McLeish, Silvia M. Uriarte, Madhavi J. Rane
-
Publication number: 20110177998Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: July 11, 2008Publication date: July 21, 2011Inventors: Ronen Shemesh, Zurit Levine, Amir Toporik, Chen Hermesh, Yossef Kliger, Eyal Gofer, Assaf Wool, Dvir Dahary, Yossi Cohen
-
Patent number: 7981861Abstract: The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.Type: GrantFiled: June 23, 2010Date of Patent: July 19, 2011Assignee: Amylin Pharmaceuticals, Inc.Inventors: Thomas R. Coolidge, Mario Ehlers
-
Publication number: 20110171292Abstract: The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention.Type: ApplicationFiled: January 27, 2011Publication date: July 14, 2011Applicant: The Research Foundation of State University of New YorkInventors: Basil Rigas, Yu Sun
-
Publication number: 20110172153Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: August 1, 2008Publication date: July 14, 2011Applicants: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Patent number: 7977455Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.Type: GrantFiled: October 30, 2007Date of Patent: July 12, 2011Assignee: IPSEN Pharma, S.A.S.Inventor: Zheng Xin Dong
-
Publication number: 20110165166Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.Type: ApplicationFiled: February 3, 2011Publication date: July 7, 2011Applicants: Serono Genetics Institute S.A., Institut National De La Sante Et De La Recherche Medicale (INSERM)Inventors: BERNARD BIHAIN, Lydie Bougueleret, Frances Yen-Potin
-
Publication number: 20110165147Abstract: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: March 1, 2011Publication date: July 7, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Maria A. Glucksmann, Inmaculada Silos-Santiago, Joseph M. Carroll, Katherine M. Galvin
-
Publication number: 20110166072Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.Type: ApplicationFiled: February 25, 2011Publication date: July 7, 2011Inventors: Woei-Jer Chuang, Wen-Mei Fu, Mannching Sherry Ku, Yen-Lun Huang
-
Publication number: 20110166061Abstract: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: April 26, 2010Publication date: July 7, 2011Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra De Meyer
-
Publication number: 20110166063Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 7, 2011Applicant: Nektar TherapeuticsInventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
-
Publication number: 20110165165Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: ApplicationFiled: December 21, 2010Publication date: July 7, 2011Applicant: Schering CorporationInventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
-
Patent number: 7972615Abstract: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.Type: GrantFiled: March 27, 2009Date of Patent: July 5, 2011Assignee: Affinergy, Inc.Inventors: Guy Orgambide, Mohmed Anwer, Shrikumar A. Nair, Paul Hamilton
-
Patent number: 7968678Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.Type: GrantFiled: December 27, 2007Date of Patent: June 28, 2011Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer ResearchInventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
-
Publication number: 20110150980Abstract: Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.Type: ApplicationFiled: November 18, 2010Publication date: June 23, 2011Applicant: VasoGenix Pharmaceuticals, Inc.Inventors: George Lee Southard, Jeffrey Lee Southard
-
Publication number: 20110154522Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.Type: ApplicationFiled: December 13, 2010Publication date: June 23, 2011Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Stanley J. Korsmeyer, Anthony Letai
-
Patent number: 7964559Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.Type: GrantFiled: March 9, 2005Date of Patent: June 21, 2011Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Carole A. Bewley